Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

When funding is tight, life sciences startups must be even more strategic with requested amounts, timing, and funding sources ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Building iteration into the product commercialization process can help life sciences companies avoid many of the missteps ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

Leadership in pharma means questioning assumptions, amplifying diverse voices, and creating environments where authenticity ...

Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...